A phase I pharmacodynamic study of CP-751, 871 as neoadjuvant treatment for early breast cancer

Trial Profile

A phase I pharmacodynamic study of CP-751, 871 as neoadjuvant treatment for early breast cancer

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2015

At a glance

  • Drugs Figitumumab (Primary)
  • Indications Early breast cancer
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Apr 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 03 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top